RU2021134402A - Клетка-естественный киллер, содержащая экзогенную митохондрию, и фармацевтическая композиция, включающая такую клетку - Google Patents
Клетка-естественный киллер, содержащая экзогенную митохондрию, и фармацевтическая композиция, включающая такую клетку Download PDFInfo
- Publication number
- RU2021134402A RU2021134402A RU2021134402A RU2021134402A RU2021134402A RU 2021134402 A RU2021134402 A RU 2021134402A RU 2021134402 A RU2021134402 A RU 2021134402A RU 2021134402 A RU2021134402 A RU 2021134402A RU 2021134402 A RU2021134402 A RU 2021134402A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- peripheral blood
- pharmaceutical composition
- blood mononuclear
- mononuclear cell
- Prior art date
Links
- 210000003470 mitochondria Anatomy 0.000 title claims 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims 5
- 210000004027 cell Anatomy 0.000 title claims 3
- 210000000822 natural killer cell Anatomy 0.000 title 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 208000035473 Communicable disease Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 210000004409 osteocyte Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Мононуклеарная клетка периферической крови, содержащая экзогенные митохондрии и по меньшей мере одну эндогенную интактную митохондрию.
2. Мононуклеарная клетка периферической крови по п. 1, где экзогенные митохондрии получены из мышечных клеток, гепатоцитов, фибробластов, эпителиальных клеток, нейронов, адипоцитов, остеоцитов, лейкоцитов, лимфоцитов, стволовых клеток или клеток слизистых оболочек.
3. Мононуклеарная клетка периферической крови по п. 1, где экзогенные митохондрии содержатся в количестве от 1 до 103 на мононуклеарную клетку периферической крови.
4. Фармацевтическая композиция для лечения злокачественной опухоли или инфекционного заболевания, включающая мононуклеарную клетку периферической крови по п. 1.
5. Фармацевтическая композиция по п. 4, где злокачественная опухоль выбрана из группы, состоящей из рака желудка, рака печени, рака легких, колоректального рака, рака молочной железы, рака предстательной железы, рака яичников, рака поджелудочной железы, рака шейки матки, рака щитовидной железы, рак гортани, острого миелогенного лейкоза, опухоли головного мозга, нейробластомы, ретинобластомы, рака головы и шеи, рака слюнных желез и лимфомы.
6. Фармацевтическая композиция по п. 4, где инфекционное заболевание выбрано из группы, состоящей из гепатита B, гепатита C, инфекции вирусом папилломы человека (HPV), инфекции цитомегаловирусом, вирусного респираторного заболевания и гриппа.
7. Способ для профилактики или лечения злокачественной опухоли или инфекционного заболевания, включающий этап введения фармацевтической композиции, которая содержит в качестве активного ингредиента мононуклеарную клетку периферической крови по п. 1, нуждающемуся в этом индивидууму.
8. Способ по п. 7, где композицию вводят путем, выбранным из группы, состоящей из внутривенного, подкожного, глазного, интраперитонеального или внутримышечного путей.
9. Способ по п. 7, где способ включает введение другого лекарственного средства или физиологически активного вещества с эффектом профилактики или лечения злокачественной опухоли или инфекционного заболевания в комбинации с клеткой.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2016-0151411 | 2016-11-14 | ||
| KR20160151411 | 2016-11-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019118070A Division RU2777371C2 (ru) | 2016-11-14 | 2017-11-14 | Клетка-естественный киллер, содержащая экзогенную митохондрию, и фармацевтическая композиция, включающая такую клетку |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2021134402A true RU2021134402A (ru) | 2022-01-14 |
Family
ID=61977886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021134402A RU2021134402A (ru) | 2016-11-14 | 2017-11-14 | Клетка-естественный киллер, содержащая экзогенную митохондрию, и фармацевтическая композиция, включающая такую клетку |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11278569B2 (ru) |
| EP (1) | EP3540048A4 (ru) |
| JP (1) | JP7074358B2 (ru) |
| KR (2) | KR101846464B1 (ru) |
| CN (1) | CN109983120A (ru) |
| RU (1) | RU2021134402A (ru) |
| WO (1) | WO2018088875A2 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200071338A (ko) | 2018-12-11 | 2020-06-19 | 주식회사 스마트셀랩 | Ｎｋ 세포 활성 조절을 통한 비만의 예방 또는 치료 방법 |
| CN114786685A (zh) * | 2019-07-09 | 2022-07-22 | 唐凌峰 | 一种基于线粒体的药物递送系统及其用途 |
| CN116096861A (zh) * | 2020-04-03 | 2023-05-09 | 赛立维公司 | 过继性细胞转移的增强 |
| KR102290596B1 (ko) | 2020-09-10 | 2021-08-19 | 주식회사 파이안바이오테크놀로지 | 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도 |
| KR102273163B1 (ko) | 2020-09-10 | 2021-07-05 | 주식회사 파이안바이오테크놀로지 | 혈소판 유래 미토콘드리아의 수득 방법 및 이의 용도 |
| AU2022361057A1 (en) * | 2021-10-06 | 2024-05-02 | Cellvie Inc. | Enhancing adoptive cell transfer by promoting a superior population of adaptive immune cells |
| KR102671551B1 (ko) * | 2022-03-11 | 2024-06-03 | 주식회사 파이안바이오테크놀로지 | 전구약물 전환 효소를 포함하는 개질된 미토콘드리아 및 이의 용도 |
| CN114699430A (zh) * | 2022-04-12 | 2022-07-05 | 重庆理工大学 | 线粒体及其在胰腺炎中的应用和应用方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8846028B2 (en) | 2010-10-28 | 2014-09-30 | The Invention Science Fund I, Llc | Mitochondrial enhancement of cells |
| JP6010136B2 (ja) * | 2011-12-22 | 2016-10-19 | モガム バイオテクノロジー インスティチュート | ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物 |
| CA2881792C (en) | 2012-08-13 | 2024-02-27 | Anthrogenesis Corporation | Natural killer cells and uses thereof |
| CN104630149B (zh) | 2013-11-08 | 2018-08-21 | 中国科学院广州生物医药与健康研究院 | 外源线粒体导入到哺乳动物细胞中的方法 |
| EP3169338A1 (en) | 2014-07-16 | 2017-05-24 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for the intercellular transfer of isolated mitochondria in recipient cells |
| US20180030413A1 (en) | 2015-02-26 | 2018-02-01 | Minovia Therapeutics Ltd. | Mammalian cells enriched with functional mitochondria |
-
2017
- 2017-11-14 EP EP17869358.6A patent/EP3540048A4/en active Pending
- 2017-11-14 CN CN201780070481.5A patent/CN109983120A/zh active Pending
- 2017-11-14 US US16/349,310 patent/US11278569B2/en active Active
- 2017-11-14 RU RU2021134402A patent/RU2021134402A/ru unknown
- 2017-11-14 WO PCT/KR2017/012883 patent/WO2018088875A2/ko unknown
- 2017-11-14 JP JP2019525738A patent/JP7074358B2/ja active Active
- 2017-11-14 KR KR1020170151503A patent/KR101846464B1/ko active IP Right Grant
-
2018
- 2018-03-22 KR KR1020180033127A patent/KR20180054523A/ko not_active Application Discontinuation
-
2021
- 2021-09-23 US US17/483,193 patent/US20220000930A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR101846464B1 (ko) | 2018-04-09 |
| US20190269731A1 (en) | 2019-09-05 |
| US11278569B2 (en) | 2022-03-22 |
| CN109983120A (zh) | 2019-07-05 |
| JP2019534029A (ja) | 2019-11-28 |
| KR20180054523A (ko) | 2018-05-24 |
| US20220000930A1 (en) | 2022-01-06 |
| RU2019118070A (ru) | 2020-12-14 |
| WO2018088875A3 (ko) | 2018-08-09 |
| EP3540048A4 (en) | 2020-06-24 |
| EP3540048A2 (en) | 2019-09-18 |
| JP7074358B2 (ja) | 2022-05-24 |
| WO2018088875A2 (ko) | 2018-05-17 |
| RU2019118070A3 (ru) | 2021-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2021134402A (ru) | Клетка-естественный киллер, содержащая экзогенную митохондрию, и фармацевтическая композиция, включающая такую клетку | |
| JP2019534029A5 (ru) | ||
| US10548853B2 (en) | Oncolytic virus formulation and preparation method thereof | |
| US8481297B2 (en) | Compositions and methods of use of an oncolytic vesicular stomatitis virus | |
| RU2018146490A (ru) | Новые генно-инженерные вирусы осповакцины | |
| JP7239910B2 (ja) | 治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用 | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| JP2019520061A5 (ru) | ||
| EP3269387A1 (en) | Polynucleotides and polypeptides for treating oncogenic viral polypeptide positive tumors | |
| MX2021011107A (es) | Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infeccion por vhb o enfermedades inducidas por vhb. | |
| WO2015095167A3 (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon | |
| MX2022006742A (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter. | |
| Palladini et al. | Cancer immunoprevention: from mice to early clinical trials | |
| Chen et al. | Antitumor effect of the Newcastle disease viral hemagglutinin–neuraminidase gene is expressed through an oncolytic adenovirus effect in osteosarcoma cells | |
| PH12020500194A1 (en) | Malaria vaccine | |
| US20220273739A1 (en) | Combination drug for treating malignant tumor, pharmaceutical composition for treating malignant tumor, and pharmaceutical composition for malignant tumor treatment | |
| KR102673991B1 (ko) | 경비 b형 간염 백신 조성물 및 그 제조방법 | |
| TWI786186B (zh) | 含單株抗體或其抗原結合片段之醫藥組成物及其用途 | |
| US20120315248A1 (en) | Compositions and methods for treating cancer with attenuated oncolytic viruses | |
| ES2852002T3 (es) | Factor estimulante de colonias para su uso en el tratamiento del cáncer de páncreas o de colon | |
| RU2526799C2 (ru) | Фармацевтическая композиция и способ получения противовирусных фракций (антивирус-с) | |
| Lollini et al. | Immunoprevention and immunotherapy of mammary carcinoma | |
| WO2017036284A1 (zh) | Epac直接或间接激动剂与溶瘤病毒的联合应用 | |
| Yılmaz | Oncolytic Virotherapy and The Immune System. | |
| CN106943400B (zh) | 增强肝癌细胞对cik细胞杀伤敏感性的化合物及其制剂 |